RRML - Platelet indices in Philadelphia-negative chronic myeloproliferative neoplasms
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12


Advanced search


Top 10 downloaded articles
- February 2024 -
 
Anti-thyroid peroxidase (TPO) ... 18
Romanian Review of Laboratory ... 14
Recomandarea comună EFLM-COLA... 13
Identification of shared hub g... 12
Challenges in prophylactic the... 10
Approaching Risk Management in... 9
Monocyte to high-density lipop... 8
Understanding the key differen... 7
Understanding the pathogenesis... 7
Atellica CH 930 chemistry anal... 6

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 23(2)/2015 DOI:10.1515/rrlm-2015-0012
XML
TXT

Platelet indices in Philadelphia-negative chronic myeloproliferative neoplasms

Ariela-Ligia Olteanu, Romeo-Gabriel Mihaila, Alina-Camelia Catana, Ofelia Flucus, Cristina Bus, Manuela Mihalache


Abstract:

Introduction: Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN): polycythemia vera (PV), essential thrombocythaemia (ET), and primary myelofibrosis (PMF) are characterized by an increased rate of thrombosis complications partly due to platelets activation. Large platelets are more active, have an enhanced procoagulant function and have a pathogenic role in arterial and venous thrombosis. In our study we tried to establish if platelet volume indices (MPV, PDW, P-LCR) issued from automated complete blood count determination are significantly different in Ph-MPN patients in comparison to healthy subjects. Materials and methods: Blood cell counts including platelet volume indices were assessed for 102 Ph-MPN and 102 healthy subjects using the impedance method on Sysmex XS 1000i and glucose and lipid profile, were assessed on Architect c 8000. Assessement of JAK2V617 positivity was conducted with amplification refractory mutation system polymerase chain reaction (ARMS-PCR), in whole peripheral blood. Results: Platelet volume indices (PVI) measured with the impedance based method, did not show significant differences in Ph-MPN patients in comparison to healthy controls. We noticed a moderate correlation between these indices and the presence of JAK2V617F mutation. PVI were increased in the small subgroup of patients treated with anagrelide and decreased in patients treated with simvastatin, comparatively with untreated patients. Conclusion: In our study we did not find a significant difference between platelet volume indices from Ph-MPN patients and healthy subjects. Further studies are required to demonstrate correlations between platelet volume indices and JAK2 V617F mutation, treatment with anagrelide and statins, respectively.

Keywords: chronic myeloproliferative neoplasms, platelet activation, platelet volume indices

Received: 8.1.2015
Accepted: 29.5.2015
Published: 11.6.2015

 
  PDF Download full text PDF
(366 KB)
     
 
How to cite
Olteanu AL, Mihaila RG, Catana AC, Flucus O, Bus C, Mihalache M. Platelet indices in Philadelphia-negative chronic myeloproliferative neoplasms. Rev Romana Med Lab. 2015;23(2):169-77. DOI:10.1515/rrlm-2015-0012